• Danielle Jolla, United States says, "I love your online pharmacy Because of your quick shipping and reasonable prices."
  • Jill Barrella, United States says, "Seemed easy to purchase, reasonable prices. Good customer service when I used it."
  • Brian Pavey, United States says, "I am very satisfied with IDM and plan on making more purchases in the future. IDMs prices are low which makes it very compelling to use over conventional pharmacies with high copays and more restrictions continually implemented."
  • Eric Gonzales, United States says, "The website is very user friendly, there is a lot of variety and checking out was easy."
  • Albert Martinez, United States says, "Very organized and efficient concerning delivery and products are great. Very satisfied, impressed with delivery and product."
  • Natalie Wallace, United States says, "I absolutely love getting my medications at a great price and I always get that here. And I recommend this site to my family and friends."
  • Ask our pharmacist, if you have any questions related to your medications
    Click to find International Shipping charges at our pharmacy.
    Shop & Earn @ InternationalDrugMart
    Easy and secure shopping @ InternationalDrugMart.com.
    Get your instant Coupon now!
    Price challenge
    You can find the latest happening of our pharmacy Visit to discuss on various diseases and conditions
    Follow us on Twitter
    You are here: Home > Pharmacy News | Health Articles/Tips > Clinical Research > October 12, 2010

      Better breast cancer drug in sight for Genentech

      Posted AtBoston.com

      Researchers reported last week on a study of 137 patients who were randomly assigned to receive the original trastuzumab (Herceptin) along with chemotherapy, or a new souped-up antibody drug called T-DM1 from Genentech, of South San Francisco, Calif., and Waltham’s ImmunoGen Inc. The study, among Women getting their first round of therapy, showed 48 percent had tumor shrinkage with the new drug; 41 percent did as well on standard treatment. Only 37 percent of women on the new drug had clinically relevant adverse events, compared with 75 percent on standard therapy.

      This is still just a mid-stage clinical trial, and researchers don’t know if the new drug is better at keeping tumors from spreading, which is the main goal.

      But it is another intriguing step forward for T-DM1, which could become one of the first drugs to successfully combine the precise targeting capability of an antibody with a super-potent toxin to kill tumor cells.

      Genentech is betting the new drug will improve upon the original, which generates more than $5 billion in annual sales.

      “We are encouraged by the results,’’ Edith Perez, a researcher at the Mayo Clinic and the lead investigator of the trial, said in a statement. “The study demonstrated that T-DM1 has very good antitumor activity as well as much lower toxicity.’’

      Genentech had hoped to win FDA approval of T-DM1 based on a separate study that showed promising tumor shrinkage in much sicker patients who were receiving their third round of therapy.

      But in August, the FDA said it would not consider that application for a faster-than-usual approval. That study continues.

      Genentech is also testing its new drug on more than 1,000 patients receiving their initial round of treatment.

      Oct 12, 2010


      Share this Article!

    Back to top^